This study is testing if adding bethanechol to standard chemotherapy (gemcitabine and nab-paclitaxel) can improve the removal of pancreatic cancer during surgery. Researchers want to see if bethanechol, which has shown promise in animal studies, can help shrink tumors and make surgery more successful. You may be able to join if you have pancreatic ductal adenocarcinoma, are planning to receive chemotherapy before surgery, and can take oral medications. The main goal is to see how many patients have all their cancer removed (R0 resection rate) after 36 months. The study is also looking at the safety of bethanechol when combined with these chemotherapy drugs. The current status of this study is unclear, and it plans to enroll 37 participants.

Study design

This study is an interventional trial with an unclear phase, planning to enroll 37 participants. It is testing bethanechol in combination with gemcitabine and nab-paclitaxel.

What's involved

You would take bethanechol tablets twice daily, one hour before morning and evening meals. Chemotherapy with gemcitabine and nab-paclitaxel would be given on days 1, 8, and 15 of each cycle.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, R0 resection rate, will be measured at 36 months, suggesting a follow-up period of at least that long.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.